Modality
ERT
MOA
HPK1i
Target
IL-23
Pathway
RNA Splicing
HNSCCAS
Development Pipeline
Preclinical
~Jan 2016
→ ~Apr 2017
Phase 1
~Jul 2017
→ ~Oct 2018
Phase 2
Jan 2019
→ Jul 2029
Phase 2Current
NCT06699395
838 pts·AS
2023-12→2025-07·Completed
NCT04565941
549 pts·HNSCC
2019-01→2029-07·Terminated
1,387 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-228mo agoPh2 Data· AS
2029-07-173.3y awayPh2 Data· HNSCC
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Termina…
P2
Complet…
Catalysts
Ph2 Data
2025-07-22 · 8mo ago
AS
Ph2 Data
2029-07-17 · 3.3y away
HNSCC
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06699395 | Phase 2 | AS | Completed | 838 | EASI-75 |
| NCT04565941 | Phase 2 | HNSCC | Terminated | 549 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 |